Skip to content Skip to footer
Subscribe Now
INSIGHTS+

EMA Marketing Authorization of New Drugs in January 2026    

Shots:  The European Commission approved multiple therapies across vaccines, rare diseases, endocrinology, and immunology, including products from BioNet, Sanofi, Fondazione Telethon, IntraBio, and Ionis / Otsuka.  The Committee for Medicinal Products for Human Use also issued positive opinions for late-stage assets from UCB and Gedeon Richter, with additional recommendations supporting Sanofi’s Rezurock.  Decisions were backed by strong Phase II/III data…
February 17, 2026

Read more

INSIGHTS+

2025 EMA Drug Approvals Outlook: A Year of Intentional, Biology Led Medicine Across Europe 

Shots:  EMA approvals in 2025 reinforce a biology-first regulatory standard, favoring mutation-exact, genotype-defined, and severity-weighted therapies that narrow indications, elevate rare diseases, and reward durability of benefit over rapid market expansion  Convenience at the EMA is no longer cosmetic, it is integral to benefit–risk assessment, with oral, subcutaneous, and low-burden dosing strategies increasingly tied to adherence, long-term outcomes,…
January 22, 2026

Read more

INSIGHTS+

The US FDA New Drug Approvals in December 2025 

Shots:  Innovation peaked in December 2025, as the FDA delivered a wave of approvals spanning cardiometabolic disease, infectious disease, respiratory immunology, rare hematologic disorders, and acute cardiovascular and neurologic conditions highlighting both scientific breadth and clinical precision  Seven notable therapies crossed the regulatory finish line, including LIB Therapeutics’ Lerochol for LDL lowering, Innoviva’s Nuzolvence for gonorrhea, GSK’s Exdensur for asthma with eosinophilic phenotype, Cytokinetics’ Myqorzo…
January 13, 2026

Read more

NEWS

Chiesi Group Enters a ~$2.1B Deal with Arbor Biotechnologies to Develop Novel Rare Disease Gene Editing Programs

Shots: Chiesi Group has entered into an exclusive global collaboration & license deal with Arbor for ABO-101 in primary hyperoxaluria type 1 (PH1) & a multitarget option to use Arbor’s gene editing platform for developing liver-targeted therapies for rare diseases As per the deal, Chiesi will obtain exclusive rights to develop & commercialize ABO-101 for PH1…
October 7, 2025

Read more

Disease of the Month – Gaucher Disease
INSIGHTS+

Disease of the Month – Gaucher Disease

Shots:  Gaucher disease is a rare, autosomal recessive disorder that enlarges organs like the bone marrow, liver, and spleen by depositing fats (lipids) in them  In this reprise of our Disease of the Month report, we present an enlightening description of Gaucher disease with a thorough study of epidemiology, market size, disease management, potential medicines,…
August 28, 2024

Read more

New Drug Designations - September 2023
INSIGHTS+

New Drug Designations – September 2023

Shots:  PharmaShots' designation report provides a concise overview of several drugs and their designations by the US FDA, the EU, and China. This month’s report includes 10 biological drugs, 15 small molecules, 5 cell and gene therapies, 4 devices, 1 vaccine and 1 microbiota  MicuRx’ Contezolid and Contezolid acefosamil, focused on the treatment of Diabetic…
October 16, 2023

Read more

VIEWPOINTS_Martin Mackay_2023
VIEWPOINTS

Martin Mackay, CEO of Rallybio, Shares his Thoughts on the Appointment of Jonathan I. Lieber as Chief Financial Officer

Shots: Martin shared his views on the appointment of Jonathan I. Lieber as the CFO of Rallybio. Martin spoke about Jonathan's educational background and experience while talking to PharmaShots' team He also talked about how Jonathan I. Lieber’s expertise in finance, capital raising, long-range strategic planning, operations, and investor relations can contribute to the long-term…
April 10, 2023

Read more

PharmaShots Interview Insmed’s Martina Flammer Shares Insights on New Affordable Drugs for Rare Diseases
VIEWPOINTS

PharmaShots Interview: Insmed’s Martina Flammer Shares Insights on New Affordable Drugs for Rare Diseases

In an interview with PharmaShots, Martina Flammer, Chief Medical Officer at Insmed share her views on the R&D continuum to develop new drugs for rare diseases and also highlights its business pillars Shots: The idea of the continuum is that all department works together to develop the drugs which will be helpful not only for the company but for patients too In…
January 11, 2022

Read more